Quick Approval for COVID Vaccines a Concern, Rare Disease Patients Say
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less…
Articles by Patricia Inacio, PhD
EveryLife Scholarship Fund Open Until May 7 for Adults With Rare Diseases in US
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a…
Soliris Effective and Safe in Real-world Use, Japanese Study Reports
Soliris (eculizumab) was found in a real-world setting to safely and effectively treat adults with generalized myasthenia gravis…
Certain Immune Cells May Be Biomarker for MG Severity
Blood levels of certain immune cells, called follicular helper T-cells (Tfh), are abnormally high in patients with myasthenia gravis (MG) …
High AChR Autoantibodies Linked to MG Risk After Thymectomy
High levels of autoantibodies against acetylcholine receptors (AChR) in the blood of people with thymoma — a tumor of the thymus —…
Low Frequency of Certain Immune Cells May Help Identify MG
Lower frequency of a specific subset of immune cells in the bloodstream may help identify myasthenia gravis (MG) in…
MG Can Develop in Certain Blood Cancer Patients, Study Suggests
Myasthenia gravis (MG) can develop in people with polycythemia vera (PV), a type of blood cancer, even in the…
Dosing Begins in Phase 2 Trial of Mezagitamab, Antibody to Treat MG
A first person has been dosed in a Phase 2 trial evaluating mezagitamab (TAK-079), Takeda Pharmaceutical’s investigational antibody, as…
Dosing Begins in Phase 2 Trial Testing Batoclimab for Myasthenia Gravis
A Phase 2 clinical trial of Harbour BioMed‘s investigational therapy batoclimab, also known as HBM9161, for myasthenia…
Dutch Trial to Test NMD670 Oral Treatment Candidate
NMD Pharma is launching a Phase 1/2a trial in the Netherlands to evaluate for the first time NMD670, an…